Please ensure Javascript is enabled for purposes of website accessibility

Drug Developers Want a Bailout, Too

By Brian Orelli, PhD - Updated Apr 5, 2017 at 8:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Seriously, who isn't angling for Federal cash now?

Need a sign of how bad the economy's looking? Now, companies from perhaps the most recession-resistant industry -- health care -- want a government bailout of their own.

Drug developers apparently figured that if automakers like General Motors, homebuilders like Toll Brothers, and financial companies like Bank of America (NYSE: BAC) were all asking for bailouts ... they might as well stick their hands out, too. The industry's trade group, the Biotechnology Industry Organization (BIO), headed to Washington yesterday to ask for a handout for drug companies in the next stimulus package.

The bailout won't help profitable companies like Pfizer (NYSE: PFE), Biogen Idec (Nasdaq: BIIB), or Amgen (Nasdaq: AMGN). Instead the proposal is designed to lend a hand to small drug developers like Exelixis (Nasdaq: EXEL) and Seattle Genetics. Cash-strapped companies want up-front cash from the government now, in exchange for the net operating loss (NOL) credits that they would normally be able to use once they become profitable.

To make the proposal a little more palatable to the government, the exchange wouldn't be one-for-one; since plenty of drugmakers never become profitable, lots of NOLs go unused. Should the legislation go through, it'll be interesting to see whether companies on the verge of profitability, like Elan or Amylin Pharmaceuticals (Nasdaq: AMLN), forgo the initial cash to take the full credit down the road.

As an investor in drug developers, I feel conflicted about this. On one hand, the government already gives companies a research tax credit, and this new request seems like less of a handout than that. On the other hand, since when did capitalism stop applying to whole swaths of the market? With share prices in shambles, Johnson & Johnson (NYSE: JNJ) has been shrewdly adding to its suite of companies. And several other large pharma companies have the cash to either purchase their tinier brethren outright, or invest in their drug-development programs.

As a taxpayer, I wonder where and when the bailout mania will end. Next thing you know, the government will be handing out subsidies to oil companies to compensate for $50-a-barrel crude, and subsidizing beer drinkers because Homer Simpson asked them to.

More bailout Foolishness:

Pfizer is a pick of the Income Investor and Inside Value newsletters. Johnson & Johnson and Bank of America are also  Inside Value picks. Exelixis is a Rule Breakers recommendation. Biogen Idec is a Stock Advisor selection. The Fool owns shares of Pfizer and Exelixis. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy. Mmm... disclosure. *drooling sound*

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bank of America Corporation Stock Quote
Bank of America Corporation
BAC
$36.28 (-0.36%) $0.13
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$166.77 (-0.48%) $0.81
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$48.58 (-1.40%) $0.69
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$216.34 (-0.57%) $-1.24
Amgen Inc. Stock Quote
Amgen Inc.
AMGN
$249.70 (-0.35%) $0.88
Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$19.22 (-0.47%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.